Ophthalmic Drugs Market

Ophthalmic Drugs Market (Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, and Diabetic Retinopathy), Allergy, and Uveitis; Therapeutic Class - Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs and Anti-bacterial Drugs), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, and Combined Medication), Anti-allergy Drugs, and Anti-VEGF Agents; Product Type - Prescription Drugs and Over-the-Counter Drugs; Distribution Channel - Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Rep Id : TMRGL1769
  • Published On : Jul 2017
  • No. of Pages : 243
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.4. Trends
     4.5. Global Ophthalmic Drugs Market Analysis and Forecasts, 2015–2025
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis
     4.7. Market Outlook
     4.8. Global Company Share Analysis: Glaucoma; 2016
     4.9. Pipeline Analysis: Major Market Players
     4.10. Pipeline Analysis: Emerging Market Players
     4.11. Comparison matrix for product offerings: Major Market Players
     4.12. Snapshot: Causes of blindness - Global
     4.13. Snapshot: Causes of blindness - Regional

5. Global Ophthalmic Drugs Market Analysis and Forecasts, By Disease Indication 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast by Disease Indication, 2015–2025
            5.4.1. Dry Eye
            5.4.2. Glaucoma
            5.4.3. Infection/Inflammation
            5.4.4. Retinal Disorders
                     5.4.4.1. Wet AMD
                     5.4.4.2. Dry AMD
                     5.4.4.3. Diabetic Retinopathy
                     5.4.4.4. Others
            5.4.5. Allergy
            5.4.6. Uveitis
            5.4.7. Others
     5.5. Market Attractiveness by Disease Indication 

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Therapeutic Class 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast By Therapeutic Class, 2015–2025
            6.4.1. Anti-inflammatory Drugs
                     6.4.1.1. NSAID
                     6.4.1.2. Steroids
            6.4.2. Anti-infective Drugs
                     6.4.2.1. Anti-fungal Drugs
                     6.4.2.2. Anti-bacterial Drugs
                     6.4.2.3. Others
            6.4.3. Anti-glaucoma Drugs
                     6.4.3.1. Alpha Agonist
                     6.4.3.2. Beta Blockers
                     6.4.3.3. Prostaglandin Analogs
                     6.4.3.4. Combined Medication
                     6.4.3.5. Others
            6.4.4. Anti-allergy Drugs
            6.4.5. Anti-VEGF Agents
            6.4.6. Others
     6.5. Market Attractiveness by Therapeutic Class 

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast by Product Type, 2015–2025
            7.4.1. Prescription Drugs
            7.4.2. OTC Drugs
     7.5. Market Attractiveness by Product Type 

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channels 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Key Trends
     8.4. Market Value Forecast by Distribution Channels, 2015–2025
            8.4.1. Hospital Pharmacies
            8.4.2. Online Pharmacies
            8.4.3. Independent Pharmacies & Drug Stores
     8.5. Market Attractiveness by Distribution Channels 

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region
     9.1. Key Findings
     9.2. Policies and Regulations
     9.3. Market Value Forecast by Region
            9.3.1. North America 
            9.3.2. Europe 
            9.3.3. Asia Pacific 
            9.3.4. Latin America 
            9.3.5. Middle East and Africa 
     9.4. Market Attractiveness by Country/Region

10. North America Ophthalmic Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Key Trends
     10.2. Market Value Forecast by Disease Indication, 2015–2025
            10.2.1. Dry Eye
            10.2.2. Glaucoma
            10.2.3. Infection/Inflammation
            10.2.4. Retinal Disorders
                     10.2.4.1. Wet AMD
                     10.2.4.2. Dry AMD
                     10.2.4.3. Diabetic Retinopathy
                     10.2.4.4. Others
            10.2.5. Allergy
            10.2.6. Uveitis
            10.2.7. Others
     10.3. Market Value Forecast by Therapeutic Class, 2015–2025
            10.3.1. Anti-inflammatory Drugs
                     10.3.1.1. NSAID
                     10.3.1.2. Steroids
            10.3.2. Anti-infective Drugs
                     10.3.2.1. Anti-fungal Drugs
                     10.3.2.2. Anti-bacterial Drugs
                     10.3.2.3. Others
            10.3.3. Anti-glaucoma Drugs
                     10.3.3.1. Alpha Agonist
                     10.3.3.2. Beta Blockers
                     10.3.3.3. Prostaglandin Analogs
                     10.3.3.4. Combined Medication
                     10.3.3.5. Others
            10.3.4. Anti-allergy Drugs
            10.3.5. Anti-VEGF Agents
            10.3.6. Others
     10.4. Market Value Forecast by Product Type, 2015–2025
            10.4.1. Prescription Drugs
            10.4.2. OTC Drugs
     10.5. Market Value Forecast by Distribution Channels, 2015–2025
            10.5.1. Hospital Pharmacies
            10.5.2. Online Pharmacies
            10.5.3. Independent Pharmacies & Drug Stores
     10.6. Market Value Forecast by Country, 2015–2025
            10.6.1. U.S.
            10.6.2. Canada
     10.7. Market Attractiveness Analysis 
            10.7.1. By Disease Indication 
            10.7.2. By Therapeutic Class 
            10.7.3. By Product Type 
            10.7.4. By Distribution Channels 
            10.7.5. By Country

11. Europe Ophthalmic Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Key Trends
     11.2. Market Value Forecast by Disease Indication, 2015–2025
            11.2.1. Dry Eye
            11.2.2. Glaucoma
            11.2.3. Infection/Inflammation
            11.2.4. Retinal Disorders
                     11.2.4.1. Wet AMD
                     11.2.4.2. Dry AMD
                     11.2.4.3. Diabetic Retinopathy
                     11.2.4.4. Others
            11.2.5. Allergy
            11.2.6. Uveitis
            11.2.7. Others
     11.3. Market Value Forecast by Therapeutic Class, 2015–2025
            11.3.1. Anti-inflammatory Drugs
                     11.3.1.1. NSAID
                     11.3.1.2. Steroids
            11.3.2. Anti-infective Drugs
                     11.3.2.1. Anti-fungal Drugs
                     11.3.2.2. Anti-bacterial Drugs
                     11.3.2.3. Others
            11.3.3. Anti-glaucoma Drugs
                     11.3.3.1. Alpha Agonist
                     11.3.3.2. Beta Blockers
                     11.3.3.3. Prostaglandin Analogs
                     11.3.3.4. Combined Medication
                     11.3.3.5. Others
            11.3.4. Anti-allergy Drugs
            11.3.5. Anti-VEGF Agents
            11.3.6. Others
     11.4. Market Value Forecast by Product Type, 2015–2025
            11.4.1. Prescription Drugs
            11.4.2. OTC Drugs
     11.5. Market Value Forecast by Distribution Channels, 2015–2025
            11.5.1. Hospital Pharmacies
            11.5.2. Online Pharmacies
            11.5.3. Independent Pharmacies & Drug Stores
     11.6. Market Value Forecast by Country, 2015–2025
            11.6.1. U.K.
            11.6.2. Germany
            11.6.3. France
            11.6.4. Italy
            11.6.5. Spain
            11.6.6. Russia
            11.6.7. Rest of Europe
     11.7. Market Attractiveness Analysis 
            11.7.1. By Disease Indication 
            11.7.2. By Therapeutic Class 
            11.7.3. By Product Type 
            11.7.4. By Distribution Channels 
            11.7.5. By Country

12. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Key Trends
     12.2. Market Value Forecast by Disease Indication, 2015–2025
            12.2.1. Dry Eye
            12.2.2. Glaucoma
            12.2.3. Infection/Inflammation
            12.2.4. Retinal Disorders
                     12.2.4.1. Wet AMD
                     12.2.4.2. Dry AMD
                     12.2.4.3. Diabetic Retinopathy
                     12.2.4.4. Others
            12.2.5. Allergy
            12.2.6. Uveitis
            12.2.7. Others
     12.3. Market Value Forecast by Therapeutic Class, 2015–2025
            12.3.1. Anti-inflammatory Drugs
                     12.3.1.1. NSAID
                     12.3.1.2. Steroids
            12.3.2. Anti-infective Drugs
                     12.3.2.1. Anti-fungal Drugs
                     12.3.2.2. Anti-bacterial Drugs
                     12.3.2.3. Others
            12.3.3. Anti-glaucoma Drugs
                     12.3.3.1. Alpha Agonist
                     12.3.3.2. Beta Blockers
                     12.3.3.3. Prostaglandin Analogs
                     12.3.3.4. Combined Medication
                     12.3.3.5. Others
            12.3.4. Anti-allergy Drugs
            12.3.5. Anti-VEGF Agents
            12.3.6. Others
     12.4. Market Value Forecast by Product Type, 2015–2025
            12.4.1. Prescription Drugs
            12.4.2. OTC Drugs
     12.5. Market Value Forecast by Distribution Channels, 2015–2025
            12.5.1. Hospital Pharmacies
            12.5.2. Online Pharmacies
            12.5.3. Independent Pharmacies & Drug Stores
     12.6. Market Value Forecast by Country, 2015–2025
            12.6.1. India
            12.6.2. China
            12.6.3. Japan
            12.6.4. Australia & New Zealand
            12.6.5. Rest of Asia Pacific
     12.7. Market Attractiveness Analysis 
            12.7.1. By Disease Indication 
            12.7.2. By Therapeutic Class 
            12.7.3. By Product Type 
            12.7.4. By Distribution Channels 
            12.7.5. By Country

13. Latin America Ophthalmic Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
            13.1.3. Key Trends
     13.2. Market Value Forecast by Disease Indication, 2015–2025
            13.2.1. Dry Eye
            13.2.2. Glaucoma
            13.2.3. Infection/Inflammation
            13.2.4. Retinal Disorders
                     13.2.4.1. Wet AMD
                     13.2.4.2. Dry AMD
                     13.2.4.3. Diabetic Retinopathy
                     13.2.4.4. Others
            13.2.5. Allergy
            13.2.6. Uveitis
            13.2.7. Others
     13.3. Market Value Forecast by Therapeutic Class, 2015–2025
            13.3.1. Anti-inflammatory Drugs
                     13.3.1.1. NSAID
                     13.3.1.2. Steroids
            13.3.2. Anti-infective Drugs
                     13.3.2.1. Anti-fungal Drugs
                     13.3.2.2. Anti-bacterial Drugs
                     13.3.2.3. Others
            13.3.3. Anti-glaucoma Drugs
                     13.3.3.1. Alpha Agonist
                     13.3.3.2. Beta Blockers
                     13.3.3.3. Prostaglandin Analogs
                     13.3.3.4. Combined Medication
                     13.3.3.5. Others
            13.3.4. Anti-allergy Drugs
            13.3.5. Anti-VEGF Agents
            13.3.6. Others
     13.4. Market Value Forecast by Product Type, 2015–2025
            13.4.1. Prescription Drugs
            13.4.2. OTC Drugs
     13.5. Market Value Forecast by Distribution Channels, 2015–2025
            13.5.1. Hospital Pharmacies
            13.5.2. Online Pharmacies
            13.5.3. Independent Pharmacies & Drug Stores
     13.6. Market Value Forecast by Country, 2015–2025
            13.6.1. Brazil
            13.6.2. Mexico
            13.6.3. Rest of Latin America
     13.7. Market Attractiveness Analysis 
            13.7.1. By Disease Indication 
            13.7.2. By Therapeutic Class 
            13.7.3. By Product Type 
            13.7.4. By Distribution Channels 
            13.7.5. By Country

14. Middle East and Africa Ophthalmic Drugs Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
            14.1.2. Policies and Regulations
            14.1.3. Key Trends
     14.2. Market Value Forecast by Disease Indication, 2015–2025
            14.2.1. Dry Eye
            14.2.2. Glaucoma
            14.2.3. Infection/Inflammation
            14.2.4. Retinal Disorders
                     14.2.4.1. Wet AMD
                     14.2.4.2. Dry AMD
                     14.2.4.3. Diabetic Retinopathy
                     14.2.4.4. Others
            14.2.5. Allergy
            14.2.6. Uveitis
            14.2.7. Others
     14.3. Market Value Forecast by Therapeutic Class, 2015–2025
            14.3.1. Anti-inflammatory Drugs
                     14.3.1.1. NSAID
                     14.3.1.2. Steroids
            14.3.2. Anti-infective Drugs
                     14.3.2.1. Anti-fungal Drugs
                     14.3.2.2. Anti-bacterial Drugs
                     14.3.2.3. Others
            14.3.3. Anti-glaucoma Drugs
                     14.3.3.1. Alpha Agonist
                     14.3.3.2. Beta Blockers
                     14.3.3.3. Prostaglandin Analogs
                     14.3.3.4. Combined Medication
                     14.3.3.5. Others
            14.3.4. Anti-allergy Drugs
            14.3.5. Anti-VEGF Agents
            14.3.6. Others
     14.4. Market Value Forecast by Product Type, 2015–2025
            14.4.1. Prescription Drugs
            14.4.2. OTC Drugs
     14.5. Market Value Forecast by Distribution Channels, 2015–2025
            14.5.1. Hospital Pharmacies
            14.5.2. Online Pharmacies
            14.5.3. Independent Pharmacies & Drug Stores
     14.6. Market Value Forecast by Country, 2015–2025
            14.6.1. South Africa
            14.6.2. GCC Countries
            14.6.3. Rest of Middle East and Africa
     14.7. Market Attractiveness Analysis 
            14.7.1. By Disease Indication 
            14.7.2. By Therapeutic Class 
            14.7.3. By Product Type 
            14.7.4. By Distribution Channels 
            14.7.5. By Country

15. Competition Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Market Share Analysis by Company (2016)
     15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            15.3.1. Aerie Pharmaceuticals, Inc. 
                     15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.1.2 Financial Overview
                     15.3.1.3 Product Portfolio
                     15.3.1.4 SWOT Analysis
                     15.3.1.5 Strategic Overview
            15.3.2. ALLERGAN
                     15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.2.2 Financial Overview
                     15.3.2.3 Product Portfolio
                     15.3.2.4 SWOT Analysis
                     15.3.2.5 Strategic Overview
            15.3.3. Valeant Pharmaceuticals International, Inc.
                     15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.3.2 Financial Overview
                     15.3.3.3 Product Portfolio
                     15.3.3.4 SWOT Analysis
                     15.3.3.5 Strategic Overview
            15.3.4. Bayer AG 
                     15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.4.2 Financial Overview
                     15.3.4.3 Product Portfolio
                     15.3.4.4 SWOT Analysis
                     15.3.4.5 Strategic Overview
            15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
                     15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.5.2 Financial Overview
                     15.3.5.3 Product Portfolio
                     15.3.5.4 SWOT Analysis
                     15.3.5.5 Strategic Overview
            15.3.6. Novartis AG 
                     15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.6.2 Financial Overview
                     15.3.6.3 Product Portfolio
                     15.3.6.4 SWOT Analysis
                     15.3.6.5 Strategic Overview
            15.3.7. Pfizer Inc. 
                     15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.7.2 Financial Overview
                     15.3.7.3 Product Portfolio
                     15.3.7.4 SWOT Analysis
                     15.3.7.5 Strategic Overview
            15.3.8. Regeneron Pharmaceuticals, Inc.
                     15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.8.2 Financial Overview
                     15.3.8.3 Product Portfolio
                     15.3.8.4 SWOT Analysis
                     15.3.8.5 Strategic Overview 
            15.3.9. Santen Pharmaceutical Co., Ltd. 
                     15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.9.2 Financial Overview
                     15.3.9.3 Product Portfolio
                     15.3.9.4 SWOT Analysis
                     15.3.9.5 Strategic Overview
            15.3.10. Shire
                     15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.10.2 Financial Overview
                     15.3.10.3 Product Portfolio
                     15.3.10.4 SWOT Analysis
                     15.3.10.5 Strategic Overview
            15.3.11. Others

16. Key Take Aways

List of Tables

Table 01: Product Offering - Major Market Players
Table 02: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 03: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 04: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 05: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015–2025
Table 06: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015–2025
Table 07: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015–2025
Table 08: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 09: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 12: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 13: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 14: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 15: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015–2025
Table 16: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015–2025
Table 17: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015–2025
Table 18: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 19: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2015–2025
Table 20: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2015–2025
Table 21: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 22: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 23: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 24: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2015–2025
Table 25: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2015–2025
Table 26: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2015–2025
Table 27: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 28: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 30: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 31: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 32: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 33: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2015–2025
Table 34: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2015–2025
Table 35: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2015–2025
Table 36: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 37: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 38: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 39: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 40: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 41: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 42: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2015–2025
Table 43: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2015–2025
Table 44: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2015–2025
Table 45: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 46: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 47: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2015–2025
Table 48: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 49: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2015–2025
Table 50: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 51: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015–2025
Table 52: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015–2025
Table 53: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015–2025
Table 54: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 55: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Figures

Figure 01: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Global Company Share: Anti-glaucoma Drugs, 2016
Figure 03: Global Causes of Blindness
Figure 04: U.S. - Causes of Blindness
Figure 05: Europe - Causes of Blindness
Figure 06: Japan Causes of Blindness
Figure 07: Global Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2025
Figure 08: Global Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 09: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2015–2025
Figure 10: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2015–2025
Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2015–2025
Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2015–2025
Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2015–2025
Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2015–2025
Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2015–2025
Figure 16: Global Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 17: Global Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 19: Global Ophthalmic Drugs Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 18: Global Ophthalmic Drugs Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 20: Global Ophthalmic Drugs Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 21: Global Ophthalmic Drugs Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 22: Global Ophthalmic Drugs Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: Global Ophthalmic Drugs Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 24: Global Ophthalmic Drugs Market Value Share, by Product Type, for 2017 and 2025
Figure 25: Global Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 26: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2015–2025
Figure 27: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2015–2025
Figure 28: Global Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017 and 2025
Figure 29: Global Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2015–2025
Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2015–2025
Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2015–2025
Figure 33: Global Ophthalmic Drugs Market Value Share, by Region, for 2017 and 2025 
Figure 34: Global Ophthalmic Drugs Market Attractiveness, by Region, 2017–2025
Figure 35: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 36: North America Ophthalmic Drugs Market Attractiveness, by Country, 2017–2025
Figure 37: North America Ophthalmic Drugs Market Value Share, by Country, 2017 and 2025
Figure 38: North America Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015–2025
Figure 39: North America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 40: North America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 41: North America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 42: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 43: North America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 44: North America Ophthalmic Drugs Market Value Share, by Distribution Channels, 2017 and 2025
Figure 45: North America Ophthalmic Drugs Market Attractiveness, by Distribution Channels , 2017–2025
Figure 46: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 47: Europe Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017–2025
Figure 48: Europe Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017 and 2025
Figure 49: Europe Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025
Figure 50: Europe Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 51: Europe Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 52: Europe Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 53: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 54: Europe Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 55: Europe Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 56: Europe Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 57: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 58: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 59: Asia Pacific Ophthalmic Drugs Market Value Share, by Country/Sub-region, for 2017 and 2025
Figure 60: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2015–2025
Figure 61: Asia Pacific Ophthalmic Drugs Market Value Share, by Disease Indication, for 2017 and 2025
Figure 62: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 63: Asia Pacific Ophthalmic Drugs Market Value Share, by Therapeutic Class, for 2017 and 2025
Figure 64: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, for 2017 and 2025
Figure 65: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 66: Asia Pacific Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017 and 2025
Figure 67: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 68: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 69: Latin America Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 70: Latin America Ophthalmic Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Figure 71: Latin America Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2015–2025
Figure 72: Latin America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 73: Latin America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 74: Latin America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 75: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 76: Latin America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 77: Latin America Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 78: Latin America Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 79: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 80: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017–2025
Figure 81: Middle East & Africa Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017 and 2025
Figure 82: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2025
Figure 83: Middle East & Africa Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 84: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 85: Middle East & Africa Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 86: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 87: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 88: Middle East & Africa Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 89: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 90: Global Ophthalmic Drugs Market Share, by Company, 2016

.